Total Payments
$41,113
2024 Payments
$13,300
Companies
7
Transactions
45
Medicare Patients
560
Medicare Billing
$50,080
Payment Breakdown by Category
Consulting$19,978 (48.6%)
Other$13,450 (32.7%)
Research$4,562 (11.1%)
Travel$1,997 (4.9%)
Food & Beverage$1,027 (2.5%)
Education$99.00 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $19,978 | 6 | 48.6% |
| Honoraria | $13,450 | 9 | 32.7% |
| Unspecified | $4,562 | 7 | 11.1% |
| Travel and Lodging | $1,997 | 7 | 4.9% |
| Food and Beverage | $1,027 | 15 | 2.5% |
| Education | $99.00 | 1 | 0.2% |
Payments by Type
General
$36,550
38 transactions
Research
$4,562
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | $15,893 | 16 | $0 (2023) |
| RECORDATI_RARE_DISEASES_INC. | $13,300 | 8 | $0 (2024) |
| BIOVERATIV THERAPEUTICS INC. | $8,623 | 14 | $0 (2020) |
| GENZYME CORPORATION | $2,899 | 3 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $177.11 | 2 | $0 (2022) |
| Dova Pharmaceuticals | $122.15 | 1 | $0 (2019) |
| Pharmacyclics LLC, An AbbVie Company | $99.00 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,300 | 8 | RECORDATI_RARE_DISEASES_INC. ($13,300) |
| 2023 | $6,491 | 8 | Alnylam Pharmaceuticals Inc. ($4,923) |
| 2022 | $3,935 | 5 | Alnylam Pharmaceuticals Inc. ($2,577) |
| 2020 | $2,165 | 4 | BIOVERATIV THERAPEUTICS INC. ($2,165) |
| 2019 | $15,222 | 20 | Alnylam Pharmaceuticals Inc. ($8,393) |
All Payment Transactions
45 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | RECORDATI_RARE_DISEASES_INC. | PANHEMATIN (Drug) | Honoraria | Cash or cash equivalent | $2,100.00 | General |
| Category: METABOLIC AGENT | ||||||
| 11/12/2024 | RECORDATI_RARE_DISEASES_INC. | PANHEMATIN (Drug) | Honoraria | Cash or cash equivalent | $2,100.00 | General |
| Category: METABOLIC AGENT | ||||||
| 09/19/2024 | RECORDATI_RARE_DISEASES_INC. | PANHEMATIN (Drug) | Honoraria | Cash or cash equivalent | $2,800.00 | General |
| Category: METABOLIC AGENT | ||||||
| 07/16/2024 | RECORDATI_RARE_DISEASES_INC. | PANHEMATIN (Drug) | Honoraria | Cash or cash equivalent | $1,750.00 | General |
| Category: METABOLIC AGENT | ||||||
| 07/16/2024 | RECORDATI_RARE_DISEASES_INC. | PANHEMATIN (Drug) | Honoraria | Cash or cash equivalent | $350.00 | General |
| Category: METABOLIC AGENT | ||||||
| 05/09/2024 | RECORDATI_RARE_DISEASES_INC. | PANHEMATIN (Drug) | Honoraria | Cash or cash equivalent | $1,750.00 | General |
| Category: METABOLIC AGENT | ||||||
| 05/09/2024 | RECORDATI_RARE_DISEASES_INC. | PANHEMATIN (Drug) | Honoraria | Cash or cash equivalent | $350.00 | General |
| Category: METABOLIC AGENT | ||||||
| 04/11/2024 | RECORDATI_RARE_DISEASES_INC. | PANHEMATIN (Drug) | Honoraria | Cash or cash equivalent | $2,100.00 | General |
| Category: METABOLIC AGENT | ||||||
| 10/17/2023 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,568.00 | General |
| 04/04/2023 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $4,420.00 | General |
| 03/05/2023 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $249.03 | General |
| 03/04/2023 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $45.00 | General |
| 03/04/2023 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $39.00 | General |
| 03/04/2023 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $24.97 | General |
| 03/04/2023 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $20.00 | General |
| 03/03/2023 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 12/11/2022 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $97.41 | General |
| Category: Genetic Disease | ||||||
| 12/11/2022 | GENZYME CORPORATION | ENJAYMO (Biological), CABLIVI | Food and Beverage | In-kind items and services | $80.89 | General |
| Category: Hematology | ||||||
| 12/11/2022 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $27.11 | General |
| Category: Rare Disease | ||||||
| 08/16/2022 | GENZYME CORPORATION | ENJAYMO (Biological) | — | In-kind items and services | $1,250.00 | Research |
| Study: A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP) • Category: Hematology | ||||||
| 07/14/2022 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Consulting Fee | Cash or cash equivalent | $2,480.00 | General |
| Category: Genetic Disease | ||||||
| 12/04/2020 | BIOVERATIV THERAPEUTICS INC. | — | — | In-kind items and services | $600.00 | Research |
| Study: Long-term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia | ||||||
| 12/04/2020 | BIOVERATIV THERAPEUTICS INC. | — | — | In-kind items and services | $318.00 | Research |
| Study: Long-term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia | ||||||
| 06/30/2020 | BIOVERATIV THERAPEUTICS INC. | — | — | In-kind items and services | $893.33 | Research |
| Study: A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP) | ||||||
| 03/31/2020 | BIOVERATIV THERAPEUTICS INC. | — | — | In-kind items and services | $353.33 | Research |
| Study: A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP) | GENZYME CORPORATION | $1,250 | 1 |
| A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP) | BIOVERATIV THERAPEUTICS INC. | $1,247 | 2 |
| Long-term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia | BIOVERATIV THERAPEUTICS INC. | $918.00 | 2 |
| A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia | BIOVERATIV THERAPEUTICS INC. | $750.00 | 1 |
| A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP) | BIOVERATIV THERAPEUTICS INC. | $397.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 121 | 158 | $30,209 | $10,332 |
| 2022 | 3 | 124 | 164 | $32,241 | $11,337 |
| 2021 | 5 | 147 | 162 | $34,331 | $12,228 |
| 2020 | 3 | 168 | 218 | $50,305 | $16,183 |
Total Patients
560
Total Services
702
Medicare Billing
$50,080
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 74 | 109 | $15,149 | $5,079 | 33.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 23 | 23 | $8,326 | $2,943 | 35.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 26 | $6,734 | $2,310 | 34.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 71 | 110 | $15,004 | $5,446 | 36.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 31 | 31 | $11,280 | $4,045 | 35.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 22 | 23 | $5,957 | $1,846 | 31.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 23 | 23 | $8,384 | $3,026 | 36.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 30 | $7,770 | $2,450 | 31.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 42 | 47 | $6,331 | $2,416 | 38.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 35 | 39 | $7,468 | $2,407 | 32.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 11 | 11 | $3,982 | $1,621 | 40.7% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 12 | 12 | $396.00 | $308.75 | 78.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 65 | 71 | $18,347 | $5,890 | 32.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 64 | 103 | $19,190 | $5,784 | 30.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 26 | 26 | $9,412 | $3,421 | 36.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 13 | 18 | $3,356 | $1,089 | 32.4% |
About Dr. Roy Smith, MD
Dr. Roy Smith, MD is a Medical Oncology healthcare provider based in Erie, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1427056688.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roy Smith, MD has received a total of $41,113 in payments from pharmaceutical and medical device companies, with $13,300 received in 2024. These payments were reported across 45 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($19,978).
As a Medicare-enrolled provider, Smith has provided services to 560 Medicare beneficiaries, totaling 702 services with total Medicare billing of $50,080. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Erie, PA
- Active Since 07/12/2005
- Last Updated 07/08/2007
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1427056688
Products in Payments
- PANHEMATIN (Drug) $13,300
- GIVLARRI (Drug) $5,853
- NO PRODUCT DISCUSSED (Drug) $5,310
- OXLUMO (Drug) $2,480
- ENJAYMO (Biological) $1,331
- SUTIMLIMAB (Drug) $1,148
- Soliris (Drug) $150.00
- Doptelet (Drug) $122.15
- Imbruvica (Drug) $99.00
- GIVLAARI (Drug) $97.41
- ULTOMIRIS (Biological) $27.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.